This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Celgene Reports Strong Third Quarter 2013 Operating And Financial Results

Net Product Sales Performance

  • REVLIMID ® sales for the third quarter increased 12 percent to $1,090 million and were driven by increased duration of therapy and overall market share gains. U.S. sales of $633 million and international sales of $457 million increased 16 percent and 8 percent, respectively.
  • ABRAXANE ® sales for the third quarter were $170 million, a 60 percent increase. U.S. sales of $132 million and international sales of $38 million increased 64 percent and 47 percent, respectively. The increase in U.S. sales was primarily driven by use in non-small cell lung cancer and new patient starts in pancreatic cancer.
  • VIDAZA ® third quarter sales were $220 million, flat compared to the same period in 2012. U.S. sales decreased 6 percent to $77 million and were impacted by the introduction of a generic to the market in September. International sales increased 4 percent to $143 million. VIDAZA ® has orphan drug exclusivity in Europe until 2018 and in Japan until 2019.
  • POMALYST ®/IMNOVID ® third quarter sales were $90 million, a 35 percent increase over the second quarter of 2013. U.S. sales were $77 million, a 33 percent increase over the second quarter of 2013. The Company received U.S. Food and Drug Administration (FDA) approval for pomalidomide under the trade name POMALYST ® in February 2013. International sales for the third quarter were $13 million. The European Commission (EC) approval for pomalidomide was granted on August 5; the trade name is IMNOVID ®.
  • THALOMID ® sales were $60 million in the third quarter.

Research and Development (R&D)

Adjusted R&D expenses were $372 million compared to $328 million for the third quarter of 2012. The increase in R&D expenses was primarily due to increased investment in clinical trials. On a GAAP basis, R&D expenses were $585 million for the third quarter of 2013 and $442 million for the same period in 2012. GAAP R&D expenses increased primarily due to higher upfront payments for collaborations.

2 of 5

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs